1. Introduction

Cross-Border Gene-Editing Tourism Governance refers to the legal, ethical, regulatory and institutional framework governing individuals, researchers, biotechnology companies and medical institutions that travel from one country to another to obtain, provide or conduct gene-editing procedures.

Gene editing involves modifying genetic material within an organism through technologies such as:

CRISPR-Cas9: A programmable system used to modify selected DNA sequences.

TALENs: Engineered enzymes used to make targeted changes in DNA.

Zinc Finger Nucleases (ZFNs): Proteins designed to target and modify specific genetic sequences.

Base editing: Technology that changes individual DNA bases without necessarily creating a double-strand break.

Prime editing: A technique capable of introducing specified genetic changes with greater flexibility.

Cross-border gene-editing tourism arises when patients or researchers travel to jurisdictions with different regulatory requirements, approval systems, costs or ethical restrictions.

For example, a patient may travel from a country where experimental germline editing is prohibited or tightly restricted to another jurisdiction where a clinic advertises genetic modification services. Such movement creates questions concerning medical consent, clinical-trial authorization, genetic privacy, parental responsibility, professional negligence, international liability and the legal status of genetically modified children.

The central governance problem is that the location where gene editing occurs may differ from the country where the patient lives, the clinic is incorporated, the genetic material originates or the consequences of the intervention become apparent.

Cross-border governance therefore requires coordination between domestic law, international human-rights principles, biotechnology regulation and private international law.

2. Meaning and Nature of Gene-Editing Tourism

Gene-editing tourism is a specialised form of medical tourism involving access to genetic modification technologies across national borders.

It can be divided into several categories.

A. Somatic gene-editing tourism

Somatic gene editing modifies cells other than reproductive cells. Its intended effects are generally limited to the treated individual and are not ordinarily inherited by future generations.

Examples include:

Gene editing for inherited blood disorders.

Experimental cancer treatments.

Genetic modification of immune cells.

Treatment of certain metabolic disorders.

Gene-editing interventions involving particular tissues.

Somatic interventions may be legally permitted when the relevant medicinal-product, clinical-trial, manufacturing and medical-practice requirements are satisfied.

B. Germline gene-editing tourism

Germline editing involves modifying reproductive cells, embryos or genetic material in a manner capable of transmission to future generations.

This category raises particularly serious governance concerns because changes may become heritable.

Questions include:

Whether embryo editing is legally permissible.

Whether an edited embryo may be implanted.

Whether the resulting child has enforceable legal rights.

Whether future generations can be affected without consent.

Whether the intervention constitutes an unauthorized experiment.

Whether the clinic can be held liable for unexpected genetic consequences.

C. Enhancement-oriented gene-editing tourism

Some services may be marketed for purposes beyond treating disease, including proposed modifications associated with physical characteristics, intelligence, athletic ability or longevity.

Such applications raise questions about genetic discrimination, inequality, eugenics, consumer protection and the distinction between medical treatment and human enhancement.

D. Research-oriented gene-editing tourism

Researchers may travel to jurisdictions offering access to genetic materials, specialized laboratories, embryo research facilities or less restrictive research environments.

The relevant legal issues include research ethics approval, biosafety, genetic-data transfers, intellectual-property rights and the lawful movement of biological materials.

3. International Legal Framework

There is no single comprehensive international treaty governing all forms of cross-border human gene editing. Instead, governance depends on national legislation, regional human-rights instruments and international regulatory recommendations.

A. World Health Organization (WHO)

The WHO published two important documents on 12 July 2021:

Human Genome Editing: A Framework for Governance.

Human Genome Editing: Recommendations.

These documents address somatic, germline and heritable genome editing.

The WHO framework recommends:

National regulatory oversight of human genome-editing research.

International cooperation between regulators.

Transparent registration of human genome-editing research.

Monitoring of international medical travel.

Reporting of illegal, unregistered, unethical and unsafe activities.

Protection of research participants.

Accountability of scientists, clinics and biotechnology companies.

It specifically identifies international research and medical travel as an area requiring coordinated governance.

The WHO recommendations are influential international standards but are not themselves a binding international treaty.

World Health Organization+1

B. Oviedo Convention, 1997

The Oviedo Convention is one of the most important legal instruments governing human genome interventions.

Its principal provisions include:

Article 13 is particularly important.

It permits interventions on the human genome for preventive, diagnostic or therapeutic purposes only if their aim is not to introduce modifications into the genome of descendants.

Consequently, in states bound by Article 13, travelling abroad cannot simply eliminate the legal restrictions applicable to their own authorities and professionals. The precise jurisdictional consequences for private patients and foreign clinics depend on domestic implementing law.

The Convention binds its ratifying states, not every country in the world.

Human Rights and Biomedicine+2

C. UNESCO Universal Declaration on the Human Genome and Human Rights, 1997

The UNESCO Declaration establishes important principles concerning:

Human dignity.

Human genetic identity.

Genetic privacy.

Freedom from genetic discrimination.

Scientific responsibility.

Protection of future generations.

Article 1 describes the human genome as the heritage of humanity in a symbolic sense.

Article 11 addresses practices contrary to human dignity, including reproductive human cloning.

Although the Declaration is not a binding international treaty, it provides an important ethical foundation for national biotechnology legislation.

D. International Covenant on Civil and Political Rights (ICCPR)

The ICCPR is relevant to cross-border gene-editing governance through:

Article 7: Protection against non-consensual medical or scientific experimentation.

Article 17: Protection of privacy.

Article 24: Special protection of children.

Article 26: Equality before the law.

A country may have human-rights obligations concerning its own regulatory authorities, medical institutions and persons under its jurisdiction.

E. International research and biosafety standards

Other relevant instruments include:

Declaration of Helsinki.

CIOMS International Ethical Guidelines.

Cartagena Protocol on Biosafety, where applicable to covered living modified organisms.

International human-rights standards concerning children and disability.

WHO standards on clinical-trial transparency and research governance.

An important distinction is that environmental biosafety regulation does not automatically authorize human clinical gene editing. Different regulatory approvals may be required.

4. Governance of Cross-Border Gene-Editing Tourism

A. Jurisdictional governance

The first problem concerns which country's law applies.

Consider the following hypothetical situation:

A patient resides in India.

The patient travels to another country for gene editing.

A foreign clinic performs the procedure.

A biotechnology company manufactures the editing product in a third country.

The patient returns to India and develops complications.

Several jurisdictions may have legal interests.

The relevant questions include:

Does the country of treatment regulate the clinic?

Does the patient's home country regulate overseas medical conduct?

Does the country of manufacture regulate the genetic product?

Can the patient bring proceedings in the home country?

Can a foreign judgment be enforced against the clinic?

Which country's law determines the standard of medical care?

The applicable jurisdiction may depend on territorial jurisdiction, nationality, habitual residence, contractual terms, tort principles and statutory extraterritorial provisions.

B. Regulatory arbitrage

Regulatory arbitrage occurs when patients or biotechnology providers exploit differences between national regulatory systems.

For example, a clinic may advertise an intervention in a country with weaker oversight because the same procedure is prohibited or unavailable elsewhere.

This creates several problems:

Avoidance of clinical-trial approval.

Misrepresentation of experimental procedures as established treatment.

Inadequate informed consent.

Weak independent ethical review.

Inadequate long-term follow-up.

Difficulty recovering compensation.

Evasion of professional disciplinary systems.

An effective regulatory system must examine not only the legality of the procedure but also the marketing, recruitment, financing and post-treatment monitoring arrangements.

C. Clinical-trial authorization

A gene-editing procedure does not become lawful merely because a patient agrees to participate.

The treatment country may require:

Authorization from the national medicines regulator.

Approval of the clinical-trial protocol.

Independent ethics committee approval.

Qualified medical investigators.

Manufacturing-quality compliance.

Adverse-event reporting.

Insurance or compensation arrangements.

Long-term safety monitoring.

The legal classification of the procedure is important. A product marketed as a treatment may legally constitute an investigational medicinal product or an unauthorized clinical trial.

D. Informed consent and patient autonomy

Informed consent is a central requirement.

Patients travelling abroad must understand:

Whether the treatment is experimental.

Whether the intervention modifies somatic or germline cells.

Whether genetic changes could be inherited.

Whether off-target genetic changes are possible.

Whether long-term effects remain unknown.

Whether alternative treatments exist.

Who will pay for complications.

Whether genetic information will be transferred internationally.

Consent obtained through misleading advertising, concealment of risks or exploitation of a patient's medical vulnerability may be legally defective.

For embryo editing, parental consent also cannot resolve every ethical question concerning the interests of the future child and possible consequences for descendants.

E. Genetic privacy and international data transfers

Gene-editing tourism involves highly sensitive personal information.

Such information may include:

Whole-genome sequences.

Family genetic histories.

Embryo genetic profiles.

Hereditary disease information.

Reproductive records.

Treatment outcomes.

Genetic research datasets.

Cross-border transfer can expose individuals and relatives to privacy violations.

The governance framework should address data minimisation, lawful transfer, security, retention, secondary research use, deletion rights where applicable and restrictions on commercial exploitation.

F. Liability and compensation

Cross-border gene-editing procedures can generate several categories of liability.

A particularly difficult issue arises where a genetic complication becomes apparent many years after treatment.

Traditional limitation periods may expire before the injury is reasonably discoverable. Special rules may therefore be necessary for latent genetic injuries.

5. Important Case Laws and Judicial Decisions

There is not yet a substantial body of reported court judgments directly deciding gene-editing tourism. However, several decisions concerning reproductive autonomy, embryo research, medical experimentation, genetic privacy and cross-border reproductive services provide important legal principles.

The following cases are particularly relevant.

Case 1. Costa and Pavan v. Italy (2012)

European Court of Human Rights · Application No. 54270/10 · 28 August 2012

Facts:

The applicants were an Italian couple who were carriers of cystic fibrosis. They wished to use preimplantation genetic diagnosis (PGD) to avoid having a child affected by the disease.

Italian law restricted access to PGD for couples in their circumstances.

Legal issue:

Whether restrictions on access to reproductive genetic testing violated the right to respect for private and family life under Article 8 of the European Convention on Human Rights.

Decision:

The European Court of Human Rights found a violation of Article 8 because the Italian legal framework was inconsistent in its treatment of the applicants' reproductive choices.

Relevance to gene-editing tourism:

The case establishes that reproductive autonomy and access to genetic technologies can engage fundamental human rights.

It is relevant to situations where patients travel abroad to obtain genetic services unavailable in their home country.

However, the decision concerned embryo genetic diagnosis, not gene editing. It does not establish a right to obtain heritable genome modification.

Case 2. Parrillo v. Italy (2015)

European Court of Human Rights, Grand Chamber · Application No. 46470/11 · 27 August 2015

Facts:

The applicant wanted to donate embryos created through IVF with her deceased partner to scientific research.

Italian law prohibited the use of embryos for scientific research in the circumstances.

Legal issue:

Whether the prohibition interfered with the applicant's right to respect for private life and peaceful enjoyment of possessions.

Decision:

The Grand Chamber held that Article 8 was applicable but found no violation. It also held that the embryos could not be treated as possessions protected by Article 1 of Protocol No. 1.

The Court recognized the sensitive ethical nature of embryo research and the state's margin of appreciation.

Relevance:

The judgment is important for cross-border embryo-editing tourism because it demonstrates that:

Embryo research may be subject to strict domestic restrictions.

Scientific freedom does not automatically override embryo-protection legislation.

National authorities may have discretion in regulating reproductive biotechnology.

Embryo ownership cannot simply be treated as ordinary property ownership.

The judgment does not directly decide whether an edited embryo can be transported across borders.

Case 3. S.H. and Others v. Austria (2011)

European Court of Human Rights, Grand Chamber · Application No. 57813/00 · 3 November 2011

Facts:

The applicants challenged Austrian restrictions concerning particular assisted reproductive technologies, including egg donation and sperm donation.

Legal issue:

Whether the restrictions violated Article 8, read in conjunction with Article 14, of the European Convention on Human Rights.

Decision:

The Grand Chamber found no violation of Article 8 in the circumstances, recognizing the state's margin of appreciation in regulating medically assisted reproduction.

Relevance:

The case is significant because it recognizes that reproductive technologies may be regulated differently by different countries.

For gene-editing tourism, this supports the proposition that cross-border availability of a reproductive technology does not automatically create a legal entitlement to access that technology in the home country.

Case 4. Evans v. United Kingdom (2007)

European Court of Human Rights, Grand Chamber · Application No. 6339/05 · 10 April 2007

Facts:

The applicant had embryos created using her eggs and her former partner's sperm. Following the breakdown of their relationship, the former partner withdrew consent to their continued storage and use.

Legal issue:

Whether the legal requirement for continuing consent to embryo use violated the applicant's rights under Article 8.

Decision:

The Court found no violation of Article 8, accepting the UK's regulatory framework requiring the continuing consent of both genetic contributors.

Relevance:

This judgment provides important principles for embryo-related gene-editing tourism:

Consent must remain legally meaningful.

Reproductive autonomy may conflict between genetic contributors.

Embryo-related decisions require a clear statutory framework.

An initial agreement does not necessarily authorize every later reproductive intervention.

For example, consent to IVF cannot automatically be treated as consent to genome modification or implantation of a genetically edited embryo.

Case 5. Baret and Caballero v. France (2023)

European Court of Human Rights · Applications Nos. 22296/20 and 37138/20 · 14 September 2023

Facts:

The applicants challenged French restrictions on posthumous assisted reproduction, including restrictions preventing the export of gametes and embryos to Spain for that purpose.

Legal issue:

Whether the domestic prohibition and restrictions on exporting reproductive material violated Article 8.

Decision:

The Court found no violation of Article 8.

Relevance:

This is particularly important for cross-border reproductive tourism.

It demonstrates that a person cannot necessarily circumvent domestic reproductive restrictions simply by exporting reproductive material to a country where the procedure is permitted.

By analogy, countries may regulate the export of embryos or reproductive materials intended for gene-editing procedures, subject to their applicable laws and international obligations.

HUDOC+1

Case 6. He Jiankui human genome-editing proceedings (China, 2019)

Chinese criminal proceedings · Shenzhen · December 2019

Facts:

Chinese scientist He Jiankui announced the birth of genetically edited twin girls following the use of CRISPR-Cas9 technology on human embryos.

The project involved editing the CCR5 gene with the stated intention of reducing susceptibility to HIV infection.

The experiment generated international concern because of the risks of unintended genetic changes, inadequate ethical oversight and the absence of sufficient scientific justification.

Legal outcome:

In December 2019, a Chinese court convicted He Jiankui of illegally practising medicine and sentenced him to three years' imprisonment and a fine.

Two collaborators also received criminal penalties.

Legal significance:

The proceedings demonstrate that human germline experimentation can attract criminal liability when it violates domestic medical and research requirements.

The case is especially important for cross-border governance because it demonstrates the need for:

International research transparency.

Verification of ethical approvals.

Accountability of researchers and clinics.

Protection of future children.

Controls on reproductive implantation.

International cooperation against unauthorized experiments.

Important distinction: This was a domestic Chinese criminal proceeding, not an international judgment establishing universal criminal jurisdiction over gene editing.

Case 7. Pretty v. United Kingdom (2002)

European Court of Human Rights · Application No. 2346/02 · 29 April 2002

Facts:

The applicant, who suffered from a degenerative disease, challenged restrictions concerning assisted suicide.

Legal issue:

The Court considered the relationship between personal autonomy, private life and the state's obligations under the European Convention on Human Rights.

Decision:

The Court did not find a violation of the Convention.

Relevance:

Although not a biotechnology case, the decision contributes to the broader discussion of bodily autonomy and medical decision-making.

It may inform arguments concerning patient autonomy in experimental medical treatment, but it does not create an unrestricted right to obtain gene-editing procedures abroad.

6. Indian Legal Framework Governing Cross-Border Gene-Editing Tourism

India has a developing biotechnology regulatory system. Human gene-editing tourism must be examined through several overlapping legal frameworks.

A. National Guidelines for Gene Therapy Product Development and Clinical Trials, 2019

These guidelines were issued by the Department of Biotechnology, ICMR and CDSCO.

They address:

Development of gene therapy products.

Preclinical safety.

Clinical-trial requirements.

Ethical review.

Informed consent.

Product quality.

Clinical monitoring.

Adverse-event reporting.

Gene-editing therapies may fall within this regulatory framework depending on their classification and intended use.

B. New Drugs and Clinical Trials Rules, 2019

The NDCT Rules regulate clinical trials and new drugs in India.

The Central Drugs Standard Control Organisation (CDSCO) plays a significant role in authorization and regulatory oversight.

Relevant requirements include:

Permission for regulated clinical trials.

Ethics committee approval.

Participant informed consent.

Compensation for trial-related injury or death.

Safety reporting.

Regulatory monitoring.

A foreign clinic cannot assume that its overseas approval automatically authorizes a clinical trial in India.

C. Environment (Protection) Act, 1986 and Rules, 1989

The Rules for the Manufacture, Use, Import, Export and Storage of Hazardous Micro-organisms/Genetically Engineered Organisms or Cells, 1989 establish India's biosafety framework.

Relevant institutions include:

Institutional Biosafety Committees (IBSCs).

Review Committee on Genetic Manipulation (RCGM).

Genetic Engineering Appraisal Committee (GEAC).

These bodies have different responsibilities depending on the research activity and organism involved.

Importantly, the biosafety framework must not be confused with clinical authorization for human gene therapy.

D. ICMR National Ethical Guidelines

The Indian Council of Medical Research's ethical guidelines provide important standards for biomedical research involving human participants.

They emphasize:

Voluntary consent.

Protection of vulnerable participants.

Scientific validity.

Independent ethics review.

Confidentiality.

Fair compensation.

Research accountability.

E. Digital Personal Data Protection Act, 2023

Genetic information may constitute digital personal data where it is processed in digital form and falls within the Act's scope.

Cross-border transfers must be assessed under the Act's applicable provisions, including Section 16 and any restrictions imposed by the Central Government.

The Act should be considered alongside any other applicable confidentiality, medical-record and research requirements.

F. Constitutional provisions

The Indian Constitution provides additional protections relevant to genetic technology.

Indian regulatory position: The official Indian Government's parliamentary response of 19 March 2026 confirms the continuing application of the 2019 gene-therapy guidelines, the 1989 biosafety rules and the NDCT Rules, 2019 to relevant gene-therapy activities.

Press Information Bureau+1

G. Important Indian Supreme Court judgments

1. Justice K.S. Puttaswamy (Retd.) v. Union of India (2017)

Supreme Court of India · (2017) 10 SCC 1

The Supreme Court recognized privacy as a fundamental right under Article 21 and Part III of the Constitution.

Application:

Genetic information can reveal highly personal information.

Genetic-data collection must satisfy applicable constitutional requirements.

Unauthorized disclosure can raise privacy concerns.

Genetic profiling may affect family members as well as the individual.

This judgment is important for overseas clinics transferring Indian patients' genetic information.

2. Samira Kohli v. Dr. Prabha Manchanda (2008)

Supreme Court of India · (2008) 2 SCC 1

The Court examined the requirements of valid medical consent.

It emphasized that consent for one medical procedure does not automatically authorize a substantially different procedure.

Application:

A patient agreeing to genetic testing or conventional fertility treatment has not necessarily consented to experimental embryo editing.

The decision is relevant to the scope, quality and validity of consent in gene-editing treatment.

3. Common Cause v. Union of India (2018)

Supreme Court of India · (2018) 5 SCC 1

The Supreme Court recognized the constitutional importance of individual autonomy and dignity in end-of-life decision-making.

Application:

The judgment contributes to the constitutional understanding of medical autonomy and bodily integrity, although it does not decide the legality of genetic modification.

4. Suchita Srivastava v. Chandigarh Administration (2009)

Supreme Court of India · (2009) 9 SCC 1

The Court recognized reproductive choice as an aspect of personal liberty under Article 21.

Application:

The judgment may inform disputes involving reproductive autonomy, genetic counselling and access to reproductive medical services.

It does not establish an absolute right to germline editing or override applicable regulatory prohibitions.

7. Major Legal Challenges in Cross-Border Gene-Editing Tourism

A. Conflict of laws

Different countries may classify the same procedure differently.

For example, one country may permit research on embryos under strict conditions, while another prohibits particular embryo-editing activities.

This creates conflict concerning:

Legality of the treatment.

Validity of consent.

Recognition of medical records.

Civil liability.

Criminal responsibility.

Recognition of reproductive outcomes.

Private international law must determine the applicable law and competent court.

B. Criminal jurisdiction and extraterritorial liability

A serious issue arises where a researcher, clinic or intermediary conducts an unlawful procedure abroad.

Questions include:

Can the patient's home country prosecute its nationals?

Can the treatment country prosecute foreign researchers?

Can criminal proceedings be initiated against intermediaries?

Can medical professionals lose their professional licences?

Can a country prohibit the importation of biological materials connected with an unlawful procedure?

The answers depend on national criminal legislation, territorial jurisdiction, nationality principles and applicable international cooperation arrangements.

C. Legal status of genetically edited children

One of the most complex questions concerns children born following experimental germline editing.

Legal questions include:

Whether the child's birth registration is affected.

Whether the child has a right to genetic information.

Whether the child can seek compensation for genetic injury.

Whether parents can authorize long-term genetic experimentation.

Whether future reproductive decisions can be restricted.

Whether the child has a right to protection against genetic discrimination.

A crucial principle is that a child cannot be denied legal personality or ordinary human rights because of the manner of conception or genetic modification.

D. Long-term monitoring and accountability

Gene-editing procedures may produce effects that become visible years after treatment.

A governance framework should therefore establish:

Long-term clinical monitoring.

Genetic safety assessments.

Follow-up obligations.

Adverse-event databases.

International reporting mechanisms.

Access to medical records.

Compensation for treatment-related injuries.

The difficulty increases when the clinic closes, the researcher relocates or the patient returns to another country.

E. Commercial exploitation and misleading advertising

Some clinics may advertise genetic enhancement or claim that experimental procedures are scientifically established.

Potential violations include:

Misleading medical advertising.

Unfair trade practices.

Fraudulent representations.

Concealment of clinical risks.

Unauthorized medical practice.

Exploitation of patients suffering from serious diseases.

Regulators should distinguish legitimate clinical research from commercially marketed procedures without adequate scientific evidence.

8. Proposed International Governance Model

A coordinated international system could be developed around the following mechanisms.

The WHO recommendations specifically identify international collaboration, human genome-editing registries, medical travel and illegal or unethical research as important governance areas.

World Health Organization+1

Proposed regulatory safeguards

1. Pre-travel disclosure

Patients should receive accurate information about whether the procedure is approved, experimental or prohibited.

2. Regulatory verification

The home country should provide accessible information about foreign clinical facilities and the legal status of advertised interventions.

3. Prohibition of unlawful reproductive implantation

Where applicable domestic law prohibits clinical heritable genome editing, regulatory authorities should prevent evasion through unauthorized embryo export, implantation or commercial arrangements.

4. International patient records

Treatment records, genetic findings and adverse events should be documented securely and made accessible to patients under applicable law.

5. Mandatory long-term follow-up

Clinics should establish appropriate follow-up arrangements before beginning high-risk interventions.

6. Cross-border compensation mechanisms

Patients should have meaningful access to remedies when foreign medical procedures result in negligence, defective products or unauthorized experimentation.

9. Distinction Between Somatic and Germline Gene-Editing Tourism

The distinction is fundamental. A country that authorizes somatic gene therapy does not thereby authorize reproductive germline modification.

10. Critical Analysis

Cross-border gene-editing tourism exposes a significant weakness in international biotechnology governance: the territorial structure of domestic law does not always correspond to the international nature of genetic technology.

A patient can travel abroad, a clinic can operate through international intermediaries, a genetic product can be manufactured elsewhere and the consequences can arise after the patient returns home.

Three structural problems deserve particular attention.

First, regulatory fragmentation.

There is no universally binding treaty establishing a uniform authorization and enforcement system for human genome editing. The WHO provides important international recommendations, while the Oviedo Convention creates binding obligations for its states parties. National regulatory differences remain substantial.

Second, intergenerational responsibility.

Germline editing potentially affects persons who cannot consent to the original intervention. Traditional medical-consent models are therefore insufficient to resolve all questions of responsibility.

Third, enforcement asymmetry.

The country where an intervention occurs may have primary regulatory control, while the country where the patient resides may bear much of the long-term healthcare and social consequences.

An effective system must therefore combine treatment-country responsibility, home-country patient protection and international regulatory cooperation.

11. Important Legal Principles Emerging from the Case Laws

12. Conclusion

Cross-Border Gene-Editing Tourism Governance is an emerging area of biotechnology law that requires coordination between international human-rights principles, medical regulation, reproductive rights, clinical-trial governance, genetic privacy and private international law.

The principal legal challenge is preventing individuals and biotechnology companies from exploiting differences between national regulatory systems to undertake unsafe, unauthorized or unethical procedures.

The WHO governance framework, Oviedo Convention, national clinical-trial legislation and judicial decisions concerning reproductive autonomy and medical consent provide important foundations.

For India, the interaction between Article 21 of the Constitution, the NDCT Rules, 2019, the National Guidelines for Gene Therapy Product Development and Clinical Trials, 2019, the ICMR ethical framework and applicable biosafety legislation is particularly significant.

Ultimately, effective governance should protect scientific research and legitimate therapeutic innovation while ensuring human dignity, informed consent, genetic privacy, intergenerational responsibility and enforceable remedies for individuals harmed by unlawful or unsafe gene-editing procedures.

13. Important Legal and Research References

For further academic and dissertation research:

World Health Organization – Human Genome Editing: A Framework for Governance (2021). Read WHO framework.

WHO – Human Genome Editing: Recommendations (2021). Read recommendations.

Council of Europe – Oviedo Convention, 1997. Read Convention.

Council of Europe – Genome Editing and Human Rights. Read genome-editing materials.

Parliamentary Assembly of the Council of Europe – Heritable Genome Editing in Human Beings (2023). Read report.

Government of India, Ministry of Science and Technology – Parliamentary response on CRISPR and gene editing (19 March 2026). Read official government response.

PRS Legislative Research – Gene-editing regulatory policy brief.

Catherine Yuk-ping Lo – Global Governance of Human Germline Genome Editing (2026). Read academic research.

Overall legal proposition: International travel cannot automatically legalize a gene-editing procedure that is unlawful in the country where it is performed. Equally, the fact that a treatment is prohibited in a patient's home country does not automatically make the patient's overseas medical travel a criminal offence. The legality of the procedure, conduct of providers, export and import of biological materials, and possible extraterritorial liability must be examined separately.